Follow-The-Filings

Security · featured owners

RANI Rani Therapeutics Hldgs Inc.

Health Care COM CL A Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • $16K
  • 1 reduce

RANI (Rani Therapeutics Hldgs Inc.) is held in 1 featured 13F book as of 2026 Q2. Farallon Capital Management is the largest tracked holder by portfolio weight. Figures are as-filed 13F, not free float.

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Farallon Capital Management 2026 Q2 <0.01% Reduce −73.5% 20,700 $16K History

1 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 19 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.07 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,3.01,5.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A DEFA 14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 1.02,3.03,5.03,5.07,9.01 Filing Doc
424B5 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,8.01 Filing Doc
8-K 1.01,2.03,3.02,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 12 rows shown

Filed Form Detail Links
4 Period Sep 27, 2026 · 2 forms Filing Doc
4 Period Aug 3, 2026 Filing Doc
4 Period Jul 21, 2026 Filing Doc
4 Period Jul 17, 2026 Filing Doc
4 Period Dec 27, 2024 Filing Doc
4 Period Jul 17, 2026 Filing Doc
4 Period Mar 27, 2026 Filing Doc
4 Period Jun 3, 2026 · 3 forms Filing Doc
4 Period May 28, 2026 · 6 forms Filing Doc
4 Period Oct 23, 2025 Filing Doc
4 Period Oct 23, 2025 · 2 forms Filing Doc
4 Period Oct 20, 2025 Filing Doc

Updated about 5 hours ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $1.03M $1.63M
Net income -$33.97M -$30.02M -$29.67M
Net margin * — -2920.0% -1817.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $50.85M $29.74M $53.32M
Total non-current assets * $7.07M $6.89M $5.3M
Total assets $57.92M $36.63M $58.62M
Total current liabilities $7.99M $19.89M $12.67M
Total non-current liabilities * $24.48M $13.25M $4.44M
Total equity $12.87M $1.99M $33.01M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$51.24M -$35.5M -$18.71M
Cash from investing $29.86M $19.81M -$7.03M
Cash from financing $0.233M $13.58M $40.3M
Net change in cash -$21.14M -$2.1M $14.56M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders